Guowei Ma

Oct 22, 2024 | tandfonline.com | Ying Zhou |Guowei Ma |Ning Su |Jiang Liu

ABSTRACTObjective By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug. Methods This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023. Results Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect.